Slingshot members are tracking this event:

Merck's osteoporosis candidate odanacatib development terminated

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The company is discontinuing the development of odanacatib, Merck’s investigational cathepsin K inhibitor for osteoporosis, and will not seek regulatory approval for its use. Merck previously reported a numeric imbalance in adjudicated stroke events in the pivotal Phase 3 fracture outcomes study in postmenopausal women. The company has decided to discontinue development after an independent adjudication and analysis of major adverse cardiovascular events confirmed an increased risk of stroke. The data from the analysis will be presented at the American Society for Bone Mineral Research (ASBMR) in September.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 02, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cathepsin K Inhibitor, Osteoporosis, Stroke, American Society For Bone Mineral Research